{{Drugbox
| IUPAC_name               = α-phenyl-1-(2-phenylethyl)-4-piperidine methanol
| image                    = Glemanserin_structure.png
| CAS_number               = 132553-86-7
| CAS_supplemental         = 
| ATC_prefix               = None
| ATC_suffix               = 
| PubChem                  = 71781
| ChemSpiderID             = 64815
| C=20 | H=25 | N=1 | O=1
| molecular_weight         = 295.419 g/mol
| smiles                   = OC(c1ccccc1)C3CCN(CCc2ccccc2)CC3
| StdInChI                 = 1S/C20H25NO/c22-20(18-9-5-2-6-10-18)19-12-15-21(16-13-19)14-11-17-7-3-1-4-8-17/h1-10,19-20,22H,11-16H2
| StdInChIKey              = AXNGJCOYCMDPQG-UHFFFAOYSA-N
| bioavailability          = 
| protein_bound            = 
| metabolism               = 
| elimination_half-life    = 
| excretion                = 
| pregnancy_category       = 
| legal_status             = 
| routes_of_administration = 
}}

'''Glemanserin''' ([[International Nonproprietary Name|INN]]) (developmental code name '''MDL-11,939''') is a [[drug]] which acts as a [[potency (pharmacology)|potent]] and [[binding selectivity|selective]] [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] [[receptor antagonist|antagonist]].<ref name="Dudley1988">{{cite journal |author1=Mark W. Dudley |author2=Norbert L. Wiech |author3=Francis P. Miller | title = Pharmacological effects of MDL 11,939: A selective, centrally acting antagonist of 5-HT2 receptors | journal = Drug Development Research | volume = 13 | issue = 1 | pages = 29–43 | year = 1988 | month = | pmid = | doi = 10.1002/ddr.430130104 | url = http://onlinelibrary.wiley.com/doi/10.1002/ddr.430130104/abstract|display-authors=etal}}</ref> The first truly selective 5-HT<sub>2A</sub> ligand to be discovered, glemanserin resulted in the development of the widely used and even more potent and selective 5-HT<sub>2A</sub> receptor antagonist [[volinanserin]] (MDL-100,907), which is a [[fluorinated]] [[structural analog|analogue]].<ref name="Olivier1997">{{cite book | author = Berend Olivier | title = Serotonin Receptors and Their Ligands | url = https://books.google.com/books?id=lfo0hGqIex0C&pg=PA167 | accessdate = 6 May 2012 | date = 10 July 1997 | publisher = Elsevier | isbn = 978-0-444-82041-9 | page = 167}}</ref> Though it was largely superseded in [[scientific research]] by volinanserin, glemanserin was investigated [[clinical trial|clinically]] for the treatment of [[generalized anxiety disorder]].<ref name="pmid7714223">{{cite journal |vauthors=Sramek JJ, Robinson RE, Suri A, Cutler NR | title = Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorder | journal = Journal of Clinical Psychopharmacology | volume = 15 | issue = 1 | pages = 20–2 |date=February 1995 | pmid = 7714223 | doi = 10.1097/00004714-199502000-00004| url = http://meta.wkhealth.com/pt/pt-core/template-journal/lwwgateway/media/landingpage.htm?issn=0271-0749&volume=15&issue=1&spage=20}}</ref> However, it was ultimately found to be ineffective and was not marketed.<ref name="pmid7714223" />

==See also==
* [[Volinanserin]]

==References==
{{Reflist|2}}


{{Serotonin receptor modulators}}

[[Category:5-HT2A antagonists]]
[[Category:Alcohols]]
[[Category:Phenol ethers]]
[[Category:Piperidines]]


{{nervous-system-drug-stub}}